Dear Colleagues,

Neurodegenerative disorders and the associated comorbidities are on the rise due to the global increase in ageing population. Most common neurodegenerative diseases include Parkinson’s and Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and frontotemporal dementia, among others. The rise in disease burden is not suitably met by novel therapeutic developments and effective treatment strategies yet. One of the most popular classes of biomolecules that has been successfully targeted in the last two decades are human protein kinases. Protein kinases are highly tractable drug targets where, overall, more than 70 small molecule inhibitors are FDA approved and several antibody therapies are currently under trial. Although a multitude of research approaches to target kinases for neurological dysfunction and neurodegeneration are underway, the complexities of developing effective drug molecules that can be delivered in the central nervous system (CNS) still remains a challenge. A complete understanding of the molecular mechanisms, signaling regulation, and structural basis of key kinase molecules involved in neuronal function will create and strengthen new avenues for developing drug targets for neurodegenerative disorders.

On this basis. we invite original research articles, reviews, and technical reports focused on protein kinases that can be validated as novel drug targets for neurodegenerative disorders.

Dr. Jeyanthy Eswaran
Dr. Meera Soundararajan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• protein kinase
• drug targets
• neurodegeneration
• Parkinson’s disease
• Alzheimer’s
• ALS
• dementia